210 related articles for article (PubMed ID: 36240067)
1. Up-regulation of the PI3K/AKT and RHO/RAC/PAK signalling pathways in CHK1 inhibitor resistant Eµ-Myc lymphoma cells.
Hunter JE; Campbell AE; Kerridge S; Fraser C; Hannaway NL; Luli S; Ivanova I; Brownridge PJ; Coxhead J; Taylor L; Leary P; Hasoon MSR; Eyers CE; Perkins ND
Biochem J; 2022 Oct; 479(19):2131-2151. PubMed ID: 36240067
[TBL] [Abstract][Full Text] [Related]
2. Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway.
Hunter JE; Campbell AE; Hannaway NL; Kerridge S; Luli S; Butterworth JA; Sellier H; Mukherjee R; Dhillon N; Sudhindar PD; Shukla R; Brownridge PJ; Bell HL; Coxhead J; Taylor L; Leary P; Hasoon MSR; Collins I; Garrett MD; Eyers CE; Perkins ND
Biochem J; 2022 Oct; 479(19):2063-2086. PubMed ID: 36240066
[TBL] [Abstract][Full Text] [Related]
3. The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma.
Hunter JE; Butterworth JA; Zhao B; Sellier H; Campbell KJ; Thomas HD; Bacon CM; Cockell SJ; Gewurz BE; Perkins ND
Oncogene; 2016 Jun; 35(26):3476-84. PubMed ID: 26522720
[TBL] [Abstract][Full Text] [Related]
4. LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice.
Thornburg NJ; Kulwichit W; Edwards RH; Shair KH; Bendt KM; Raab-Traub N
Oncogene; 2006 Jan; 25(2):288-97. PubMed ID: 16247482
[TBL] [Abstract][Full Text] [Related]
5. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.
Han SS; Yun H; Son DJ; Tompkins VS; Peng L; Chung ST; Kim JS; Park ES; Janz S
Mol Cancer; 2010 Apr; 9():97. PubMed ID: 20433747
[TBL] [Abstract][Full Text] [Related]
6. Lucidone Promotes the Cutaneous Wound Healing Process via Activation of the PI
Yang HL; Tsai YC; Korivi M; Chang CT; Hseu YC
Biochim Biophys Acta Mol Cell Res; 2017 Jan; 1864(1):151-168. PubMed ID: 27816443
[TBL] [Abstract][Full Text] [Related]
7. Myc suppression of Nfkb2 accelerates lymphomagenesis.
Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
[TBL] [Abstract][Full Text] [Related]
8. Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma.
Black EM; Joo YK; Kabeche L
Biochem J; 2022 Nov; 479(22):2345-2349. PubMed ID: 36416754
[TBL] [Abstract][Full Text] [Related]
9. Caspase-resistant ROCK1 expression prolongs survival of Eµ-Myc B cell lymphoma mice.
Mardilovich K; Naylor G; Julian L; Phinichkusolchit N; Keeshan K; Blyth K; Olson MF
Dis Model Mech; 2024 May; 17(5):. PubMed ID: 38616733
[TBL] [Abstract][Full Text] [Related]
10. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Walton MI; Eve PD; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Boxall KJ; Tall M; Swales K; Matthews TP; McHardy T; Lainchbury M; Osborne J; Hunter JE; Perkins ND; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Collins I; Garrett MD
Oncotarget; 2016 Jan; 7(3):2329-42. PubMed ID: 26295308
[TBL] [Abstract][Full Text] [Related]
11. Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B.
Jeay S; Pianetti S; Kagan HM; Sonenshein GE
Mol Cell Biol; 2003 Apr; 23(7):2251-63. PubMed ID: 12640111
[TBL] [Abstract][Full Text] [Related]
12. c-Myc dysregulation is a co-transforming event for nuclear factor-κB activated B cells.
David A; Arnaud N; Fradet M; Lascaux H; Ouk-Martin C; Gachard N; Zimber-Strobl U; Feuillard J; Faumont N
Haematologica; 2017 May; 102(5):883-894. PubMed ID: 28232371
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
[TBL] [Abstract][Full Text] [Related]
14. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.
Devlin JR; Hannan KM; Ng PY; Bywater MJ; Shortt J; Cullinane C; McArthur GA; Johnstone RW; Hannan RD; Pearson RB
FEBS J; 2013 Nov; 280(21):5307-16. PubMed ID: 23331925
[TBL] [Abstract][Full Text] [Related]
15. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells.
Bhat-Nakshatri P; Sweeney CJ; Nakshatri H
Oncogene; 2002 Mar; 21(13):2066-78. PubMed ID: 11960379
[TBL] [Abstract][Full Text] [Related]
16. Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells.
Mensink M; Anstee NS; Robati M; Schenk RL; Herold MJ; Cory S; Vandenberg CJ
Cell Death Differ; 2018 Mar; 25(4):797-808. PubMed ID: 29339775
[TBL] [Abstract][Full Text] [Related]
17. Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.
Borland G; Kilbey A; Hay J; Gilroy K; Terry A; Mackay N; Bell M; McDonald A; Mills K; Cameron E; Neil JC
Oncotarget; 2016 Apr; 7(17):22973-87. PubMed ID: 27056890
[TBL] [Abstract][Full Text] [Related]
18. B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma.
Ruddell A; Harrell MI; Furuya M; Kirschbaum SB; Iritani BM
Neoplasia; 2011 Aug; 13(8):748-57. PubMed ID: 21847366
[TBL] [Abstract][Full Text] [Related]
19. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.
Spender LC; Inman GJ
Mol Cancer Res; 2012 Mar; 10(3):347-59. PubMed ID: 22241218
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis.
Kurosu T; Nagao T; Wu N; Oshikawa G; Miura O
PLoS One; 2013; 8(11):e79478. PubMed ID: 24260231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
